Amedisys (NASDAQ:AMED – Get Rating) had its price target lowered by stock analysts at SVB Leerink from $131.00 to $117.00 in a research note issued on Friday, Stock Target Advisor reports. The firm presently has a “market perform” rating on the health services provider’s stock. SVB Leerink’s price target suggests a potential downside of 0.33% from the company’s current price.
Several other analysts also recently weighed in on the stock. StockNews.com assumed coverage on shares of Amedisys in a research report on Thursday, March 31st. They set a “hold” rating on the stock. BMO Capital Markets raised Amedisys from a “market perform” rating to an “outperform” rating and cut their target price for the company from $210.00 to $190.00 in a research report on Friday, February 25th. Royal Bank of Canada lowered their price target on Amedisys from $221.00 to $199.00 and set an “outperform” rating for the company in a research report on Friday, February 25th. Deutsche Bank Aktiengesellschaft cut their price objective on Amedisys from $230.00 to $210.00 in a report on Friday, April 29th. Finally, Credit Suisse Group decreased their target price on Amedisys from $200.00 to $195.00 and set an “outperform” rating for the company in a report on Friday, February 25th. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Amedisys currently has a consensus rating of “Buy” and a consensus price target of $189.19.
Shares of AMED opened at $117.39 on Friday. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.42. The firm has a market cap of $3.82 billion, a PE ratio of 20.20, a P/E/G ratio of 2.41 and a beta of 0.88. Amedisys has a 12 month low of $109.53 and a 12 month high of $276.21. The stock has a fifty day moving average price of $142.75 and a 200-day moving average price of $148.88.
In other news, insider David L. Kemmerly sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total transaction of $443,275.00. Following the sale, the insider now directly owns 16,336 shares in the company, valued at approximately $2,896,536.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.80% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Covestor Ltd acquired a new position in Amedisys in the 4th quarter valued at $28,000. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Amedisys by 55.3% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 233 shares of the health services provider’s stock valued at $38,000 after buying an additional 83 shares during the last quarter. Allworth Financial LP purchased a new position in shares of Amedisys in the first quarter worth about $38,000. Zullo Investment Group Inc. acquired a new position in Amedisys during the fourth quarter worth about $40,000. Finally, Confluence Wealth Services Inc. purchased a new stake in Amedisys during the 4th quarter valued at about $42,000. 90.47% of the stock is owned by institutional investors and hedge funds.
About Amedisys (Get Rating)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.